Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy

Scott T. Avecilla, Chris Ferrell, Wayne L. Chandler, Morayma Reyes

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. Copyright

Original languageEnglish (US)
Pages (from-to)572-574
Number of pages3
JournalAmerican journal of clinical pathology
Volume137
Issue number4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Keywords

  • Dabigatran
  • Thrombin inhibitor
  • Thrombin time

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy'. Together they form a unique fingerprint.

  • Cite this